Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Myelodysplastic Syndrome Market Be Worth By 2029?

The market size for myelodysplastic syndrome has seen quick expansion in previous years. Predictions showcase an increase from $2.56 billion in 2024 up to $2.85 billion in 2025, experiencing a compound annual growth rate (CAGR) of 11.0%. Factors contributing to this significant rise in the historic period includes increased cases of myelodysplastic syndrome, heightened awareness regarding treatment options, growth in healthcare expenditure, and government efforts.

The market for myelodysplastic syndrome is predicted to exhibit significant expansion in the coming years, reaching a value of $4.18 billion in 2029 with a compound annual growth rate (CAGR) of 10.1%. The predicted increase during the forecast period can be ascribed to factors such as the rising elderly population, the adoption of combined treatment methods, investments in hematologic research and the use of personalized medicine. The forecast period will also see key trends including development of innovative treatments for myelodysplastic syndrome, progress in diagnostic tools and procedures, clinical trials and joint research efforts.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp

What Market Forces Are Contributing To The Growth Of The Myelodysplastic Syndrome Market?

The rise in rare blood cancers is anticipated to fuel the expansion of the myelodysplastic syndrome (MDS) market. Hematologic malignancies, frequently known as blood cancers, have a low prevalence in the population and stem from the cells of the bone marrow, lymph nodes, and other parts of the blood and immune system. The goal of myelodysplastic syndrome (MDS) treatment is to control the disease by improving the production of blood cells and treating associated symptoms to impede the advancement of blood cancer in the bone marrow. For example, the Leukemia and Lymphoma Society, a US-based professional society, reported in September 2024 that one individual in the US is diagnosed with leukemia, lymphoma, or myeloma every three minutes. It is projected that in 2024, 187,740 individuals will confront these cancers, accounting for 9.4% of the forecasted 2,001,140 new cancer cases in the US. Consequently, the mounting incidence of blood cancer propels the growth of the myelodysplastic syndrome (MDS) market.

Which Segments Define The Structure Of The Myelodysplastic Syndrome Market?

The myelodysplastic syndromemarket covered in this report is segmented –

1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia; Myelodysplastic Syndrome With Multilineage Dysplasia; Myelodysplastic Syndrome With Ring Sideroblasts; Other Types

2) By Drug: Azacitidine; Lenalidomide; Decitabine; Deferasirox

3) By Treatment: Supportive Therapy; Growth Factors; Chemotherapy; Stem Cell Transplant; Other Treatments

4) By Route Of Administration: Oral; Injectable; Other Routes Of Administrations

5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users

Subsegments:

1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia; Patient Demographics

2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia; Patient Demographics

3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts; Treatment Options

4) By Other Types: Specific Types; Treatment Options

Which Long-Term Trends Will Play A Crucial Role In The Myelodysplastic Syndrome Market?

Mainstream companies involved in the myelodysplastic syndrome (MDS) market are innovating new treatment methods to consolidate their market standing. For instance, in August 2023, FDA approved Reblozyl (luspatercept-aamt), a novel therapy developed by Bristol Myers Squibb, a pharmaceutical firm based in the United States. It stands as the primary treatment for anemia in ESA-naïve adults with low- to intermediate-risk myelodysplastic syndromes (MDS) who might require consistent RBC transfusions. Based on the Phase 3 COMMANDS trial, Reblozyl demonstrated superior effectiveness in achieving RBC transfusion independence and an increase in hemoglobin over epoetin alfa, offering early treatment to a wider variety of patients facing anemia.

Which Firms Are Making The Biggest Impact In The Myelodysplastic Syndrome Market?

Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

Which Region Is Forecasted To Lead The Myelodysplastic Syndrome Market In The Coming Years?

North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12920&type=smp

Browse Through More Reports Similar to the Global Myelodysplastic Syndrome Market 2025, By The Business Research Company

Acute Myeloid Leukemia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Leukemia Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Chronic Lymphocytic Leukemia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lymphocytic-leukemia-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model